The Joe Rogan ExperienceJoe Rogan Experience #1136 - Hamilton Morris
CHAPTERS
- 0:01 – 1:57
Reunion, sobriety, and why long-form conversations work
Joe and Hamilton reflect on their first podcast together years earlier when they were very high, and why this time they’re staying sober. They connect the show’s success to long-form nuance versus soundbite culture.
- •Revisiting the earlier “too high” episode and its slippery conversation
- •Hamilton’s first exposure to the podcast’s scale and fan response
- •Long-form format as an antidote to clipped, filtered opinions
- •Why panel shows and short TV segments feel unnatural
- 1:57 – 3:00
TV talk shows as performance: applause signs, staging, and manufactured debate
Hamilton describes how traditional TV formats sabotage genuine discussion, using Dr. Oz and staged “versus” segments as examples. Joe adds how audiences, cue cards, and applause alter human communication.
- •Talk shows incentivize one-liners and applause over truth
- •Audience presence forces performative conversation
- •Warm-up comics and “applause” signage shaping reactions
- •Staged conflict framing (expert vs grieving parent) as a TV trope
- 3:00 – 6:29
Kratom dosing, risks, and why “someone died” isn’t a policy argument
Joe explains his current kratom use for pain and how dosage changes effects. Hamilton acknowledges deaths can occur with any widespread substance, and argues that isolated fatalities shouldn’t automatically trigger prohibition.
- •Joe’s capsule dosing and the shift from stimulant-like to intoxicating
- •How kratom-associated deaths fit into broader overdose reality
- •The fallacy of demanding ‘no one can die’ as a safety standard
- •Comparisons to water, aspirin, cannabis, and behavior-mediated risk
- 6:29 – 9:10
Freedom, harm reduction, and the opioid epidemic’s real misconceptions
They argue that adults should be allowed to take risks, and that drug policy should focus on education and harm reduction rather than moral panic. Hamilton critiques simplistic narratives around pharma culpability and “surprised” doctors.
- •Cognitive liberty: adults choosing risk like motorcycles or skydiving
- •Why lying to kids about drugs backfires on truly dangerous risks
- •Opioid crisis coverage often ignores long-known addiction realities
- •Addictive drugs can be ethically used with informed protocols
- 9:10 – 12:46
Kratom as an opioid substitute: Thai history, pronunciation, and policy backlash
Hamilton explains kratom’s opioid activity and why it can reduce dependence on more dangerous opioids. They discuss its Thai history, including prohibition tied to opium tax revenue, and concerns about attempts to ban it again.
- •Kratom’s opioid mechanism and why ‘opioid’ isn’t automatically ‘evil’
- •Thailand’s ban tied to protecting opium taxation
- •Anecdote: kratom helping an OxyContin withdrawal
- •Debate over pronunciation and cultural origins
- 12:46 – 16:32
Pharmacological determinism, set-and-setting, and rethinking “what drugs do”
Joe’s stories about functional heroin users lead into Hamilton’s critique of rigid stereotypes about substances. They explore how culture and expectation shape drug effects, with examples like PCP’s historical medical use and today’s MDMA/ketamine therapy.
- •“Heroin always ruins you” and other deterministic myths
- •Cross-cultural variability of alcohol and drug experiences
- •PCP’s Schedule II status and past psychotherapy use
- •Modern parallels: ketamine, MDMA, and psychotherapy renaissance
- 16:32 – 25:28
Scheduling absurdities, prohibition lessons, and why capitalism moves policy
They criticize Schedule I classifications (including cannabis and DMT) and connect drug scheduling to distrust in institutions. Hamilton notes prohibition’s repeated failure (including alcohol) and argues that corporate lobbying often drives legalization more than activism.
- •Schedule I as a political label, not a scientific one
- •Alcohol prohibition as a failed but informative experiment
- •Drug war’s impact on policing legitimacy (stop-and-frisk, victimless crime)
- •Corporatization/lobbying as the pragmatic engine of reform
- 25:28 – 31:31
Cannabis culture, shame, paranoia memes, and the “bad trip” debate
They discuss how social acceptance changes cannabis experiences and reduces shame. Hamilton argues the “bad trip” concept is often counterproductive, claiming difficult psychedelic experiences can be the most valuable—while acknowledging real risks for vulnerable individuals.
- •Normalization changes the subjective effects of cannabis
- •Shame and propaganda shaping a user’s set-and-setting
- •“Bad trips” as learning experiences rather than pure harm
- •Joe’s caution: psychotic breaks in susceptible individuals
- 31:31 – 38:17
Psychosis risk, screening, and what research still needs to answer
Hamilton shares a traumatic personal story of a friend’s lasting psychotic break after a high dose, emphasizing uncertainty about causality. They agree that research should identify risk factors (including genetics) and move beyond politically driven, basic “proof” studies.
- •Psychedelics as stressors that can precipitate psychosis in some people
- •Epidemiology: no clear population-wide increase in mental illness
- •Personal account of a friend who never recovered after an episode
- •Need for better screening, mechanistic research, and receptor-level understanding
- 38:17 – 1:02:08
Hamilton’s show, drug journalism’s role in bans, and the synthetic cannabinoid backlash
Hamilton explains how sensationalist journalism and outrage incentives have historically shaped drug scheduling. He argues that demonizing synthetic cannabinoids misses that they are products of prohibition and may have future therapeutic value—so careless reporting can close research doors.
- •VICE show origins vs scare-story pitches; freedom vs censorship
- •How headlines and outrage culture reward misinformation
- •Why “synthetic = bad” is an unhelpful moral binary
- •Potential regret: banning compounds that later show medical promise
- 1:02:08 – 1:06:39
Drug tests, privacy, and perverse incentives (K2, workplace screening, and misinformation)
They criticize urine and hair testing as invasive and scientifically crude, often unrelated to impairment. Hamilton argues testing incentivized synthetic cannabinoid use because it avoided detection, and notes passive exposure can even contaminate hair tests.
- •Drug testing targets off-hours behavior, not workplace impairment
- •Invasiveness and political signaling around sobriety
- •Synthetic cannabinoids’ rise tied to military/parole testing avoidance
- •Passive cannabis exposure contaminating hair tests; unreliable conclusions
- 1:06:39 – 1:19:08
Stimulants and moral stereotypes: Adderall vs meth, Trump rumors, and agency vs excuses
Hamilton challenges simplistic “one carbon away from meth” rhetoric and notes both amphetamine and methamphetamine have legitimate medical histories. They discuss how drug narratives are often used to excuse or explain public figures’ behavior, warning against over-attribution while allowing nuanced discussion of medication risks.
- •Adderall and methamphetamine similarities and Schedule II reality
- •Myths of “meth determinism” and cultural stereotyping
- •Public speculation about stimulants, judgment, and tolerance
- •Balancing agency with acknowledging drug effects (SSRIs, suicidality)
- 1:19:08 – 1:37:26
Ibogaine’s overlooked complexity: addiction interruption, Parkinson’s promise, and dosing tradeoffs
They dive deep into ibogaine’s multi-receptor pharmacology and why Schedule I restrictions block serious research. Hamilton explains flood-dose clinics versus safer long-term protocols, plus why attempts to create non-psychedelic analogs may miss key therapeutic components.
- •Ibogaine’s broad pharmacology (NMDA, 5-HT2A, transporters, GDNF)
- •Anti-addiction effects plus potential relevance to Parkinson’s disease
- •Prohibition driving risky “flood dose” clinic economics
- •18-MC and the limits of removing psychedelic/subjective components
- 1:37:26 – 1:40:59
Toad venom (5-MeO-DMT): origins, misconceptions, chemistry, and ethics
Hamilton investigates the modern origins of “bufo” use and debunks the popular ‘lick the toad’ myth, explaining the collection and drying process. He notes limited modern chemical analysis and argues synthetic 5-MeO-DMT is preferable to avoid harming wildlife and to standardize dosing.
- •Lack of solid evidence for ancient toad-venom traditions
- •How venom is collected, dried, scraped, and smoked (not ‘licked’)
- •Venom contains more than 5-MeO-DMT; unknown entourage contributions
- •Ethical and practical case for synthetic 5-MeO-DMT
- 1:40:59 – 2:13:26
DMT myths and real chemistry: ancient extraction claims, endogenous debates, and altered states without DMT
They examine claims linking biblical stories to DMT plants, with Hamilton arguing practical extraction constraints make ancient smokable DMT unlikely. They explore endogenous DMT controversies, alternative neurochemical routes to altered states, and breathwork/CO2 as a non-drug pathway used historically in psychotherapy screening.
- •Acacia/Mimosa burning vs true extraction and why “smoke from wood” likely isn’t DMT intoxication
- •Acid-base extraction basics: protonation, base, nonpolar solvent
- •Endogenous DMT: found in rats; not conclusively found in human brain
- •Holotropic breathwork, CO2 challenges, and early LSD-therapy screening
- 2:13:26 – 2:22:22
Peyote and mescaline cacti: modern religious history, brutal body load, and conservation crisis
Hamilton outlines peyote’s relatively recent spread via the Native American Church and describes the harsh physical experience (nausea, vomiting, long duration). He emphasizes peyote’s extreme slow growth and habitat threats, contrasting it with faster-growing San Pedro as a more sustainable mescaline source.
- •Native American Church peyote tradition is ~100 years old in the US
- •Peyote’s accessory alkaloids and historical medicinal claims
- •Severe nausea/body load and ceremony practices that intensify austerity
- •Conservation: slow growth, harvesting technique, land development; San Pedro as alternative
- 2:22:22 – 2:53:37
Ambien, disinhibition, and the Roseanne controversy: when drugs explain without excusing
Joe recounts Roseanne Barr’s situation and medication cocktail, arguing Ambien could contribute to out-of-character behavior. Hamilton explains Ambien’s documented delirium and disinhibition, shares personal cautionary stories, and notes surprising research on drugs modulating complex cognition (e.g., propranolol and implicit bias).
- •Ambien as explanation vs ‘excuse’ in public moral narratives
- •Documented bizarre behaviors: hallucinations, risk-taking, amnesia
- •Hamilton’s personal anecdotes showing extreme disinhibition
- •Propranolol study and the broader point: be cautious about “drugs can’t do X”
